1 completed, 1 recruiting. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Recruiting 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow STX-478: new trials by email Literature Review of STX-478 trials Research Report on STX-478
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of LY4064809 in Healthy Adult Participants LY4064809 Test Formulation, LY4064809 Reference Formulation - Healthy Participants | Phase 1 | Completed | Eli Lilly and Company | 24 | 2026-01-12 | 2026-04-20 |
| First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors STX-478, Fulvestrant, Ribociclib - Breast Cancer, Solid Tumors, Adult | Phase 1 / Phase 2 | Recruiting | Eli Lilly and Company | 880 | 2023-04-17 | 2026-07-07 |
Breast Diseases (1) · Breast Neoplasms (1) · Endometrial Neoplasms (1) · Head and Neck Neoplasms (1) · Hereditary Sensory and Autonomic Neuropathies (1) · Neoplasms (1) · Neoplasms by Site (1) · Ovarian Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1) · Uterine Cervical Neoplasms (1)
United States (2) · Belgium (1) · France (1) · Germany (1) · Ireland (1) · Italy (1) · Japan (1) · Netherlands (1) · Spain (1)
2023 (1)